Monograph Details
|
|
Respiratory Tract
> Asthma/COPD
|
|
BROVANA |
| Manufacturer |
|
Sepracor, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Long-acting β2-agonist. |
| Generic Name |
|
Arformoterol 15micrograms/2mL; soln for inh. |
| Indications |
|
Long-term maintenance treatment of bronchoconstriction due to COPD. |
| Children |
|
Not recommended. |
| Adults |
|
By nebulizer: 15micrograms by inhalation twice daily (AM & PM). Use standard jet (eg, PARI LC PLUS) nebulizer with air compressor (eg, PARI DURA-NEB 3000). Reevaluate periodically. |
| Contraindications |
|
Not for treatment of acute attacks. Do not initiate in significantly or acutely deteriorating COPD. Concomitant other long-acting β2-agonists. |
| Precautions |
|
Do not exceed recommended dose. Cardiovascular disease (esp. coronary insufficiency, arrhythmias, hypertension). Convulsive disorders. Hepatic impairment. Hyperthyroidism. Hypokalemia. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Monitor potassium. Prescribe a short-acting β2-agonist for acute symptoms; monitor for increased need. Pregnancy (Cat.C). Labor & delivery. Nursing mothers. |
| Interactions |
|
See Contraindications. Avoid other sympathomimetics (except short-acting bronchodilators). Avoid use during or within 2 weeks of MAOIs, tricyclics, others that prolong QTc interval. Antagonized by β-blockers. K+-depleting diuretics, theophylline, aminophylline, steroids may potentiate hypokalemia. |
| Adverse Reactions |
|
Asthenia, fever, bronchitis, headache, GI upset, serum K+ changes, leukocytosis, nervousness, pain, tremor, flu syndrome; cardiovascular effects (eg, increased pulse rate or BP; consider discontinuing if occurs); rarely: paradoxical bronchospasm, hypersensitivity reactions; increased risk of asthma-related death. |
| How Supplied |
|
Vials (2mL)—30 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
